PL4335517T3 - Podawanie i dawkowanie diaminofenotiazyn - Google Patents

Podawanie i dawkowanie diaminofenotiazyn

Info

Publication number
PL4335517T3
PL4335517T3 PL23212899.1T PL23212899T PL4335517T3 PL 4335517 T3 PL4335517 T3 PL 4335517T3 PL 23212899 T PL23212899 T PL 23212899T PL 4335517 T3 PL4335517 T3 PL 4335517T3
Authority
PL
Poland
Prior art keywords
diaminophenothiazines
dosage
administration
Prior art date
Application number
PL23212899.1T
Other languages
English (en)
Inventor
Claude Michel Wischik
Björn Olaf SCHELTER
Damon Jude Wischik
John Mervyn David Storey
Original Assignee
Taurx Therapeutics Management Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59399428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4335517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1612863.9A external-priority patent/GB201612863D0/en
Priority claimed from GBGB1710382.1A external-priority patent/GB201710382D0/en
Application filed by Taurx Therapeutics Management Ltd. filed Critical Taurx Therapeutics Management Ltd.
Publication of PL4335517T3 publication Critical patent/PL4335517T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00—Decoration means, markings, information elements, contents indicators
    • B65D2203/02—Labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Composite Materials (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
PL23212899.1T 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn PL4335517T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1612863.9A GB201612863D0 (en) 2016-07-25 2016-07-25 Administration and dosage of diaminophenothiazines
GBGB1710382.1A GB201710382D0 (en) 2017-06-29 2017-06-29 Administration and dosage of Diaminophenothiazines

Publications (1)

Publication Number Publication Date
PL4335517T3 true PL4335517T3 (pl) 2026-02-16

Family

ID=59399428

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17743330.7T PL3487505T3 (pl) 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn
PL23212899.1T PL4335517T3 (pl) 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17743330.7T PL3487505T3 (pl) 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn

Country Status (18)

Country Link
US (5) US11065256B2 (pl)
EP (3) EP4223297A3 (pl)
JP (1) JP7073330B2 (pl)
KR (4) KR102974404B1 (pl)
CN (2) CN116531386A (pl)
AU (3) AU2017301966B2 (pl)
CA (1) CA3031578C (pl)
DK (2) DK3487505T3 (pl)
ES (2) ES3046673T3 (pl)
FI (2) FI4335517T3 (pl)
HR (2) HRP20230628T1 (pl)
MX (2) MX385594B (pl)
MY (2) MY210565A (pl)
PL (2) PL3487505T3 (pl)
PT (2) PT3487505T (pl)
SG (1) SG11201900228YA (pl)
SI (2) SI4335517T1 (pl)
WO (1) WO2018019823A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162313A (en) 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
BR112021000802A2 (pt) * 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
CN120148902A (zh) 2018-09-05 2025-06-13 云顶道卫思诊断中心有限公司 神经系统变性疾病的网络方法
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
ES2992641T3 (en) * 2020-05-05 2024-12-16 Wista Lab Ltd Methylthioninium compounds for use in the treatment of hypoxemia
GB202006659D0 (en) * 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
EP1509232B1 (en) 2002-05-31 2008-11-19 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
CN104119294B (zh) * 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
DK2004155T3 (en) * 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
DK2853293T3 (en) 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
MY162313A (en) 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PT2954932T (pt) 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
CN101911081A (zh) 2007-11-05 2010-12-08 维斯塔实验室有限公司 用于临床试验的体系
WO2010078659A1 (en) 2009-01-12 2010-07-15 Foster Health Inc. Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
WO2010104375A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
KR20170061177A (ko) 2009-09-24 2017-06-02 위스타 레보레이토리스 리미티드 결정질 메틸티오니늄 클로라이드(메틸렌 블루) 수화물
WO2011036561A2 (en) 2009-09-24 2011-03-31 Wis Ta Laboratories Ltd. Process
DE102010062810B4 (de) 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
ES2655492T3 (es) 2010-11-30 2018-02-20 Wista Laboratories Ltd. Formulaciones que comprenden cloruro de metiltioninio
KR101888713B1 (ko) * 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions

Also Published As

Publication number Publication date
EP3487505B1 (en) 2023-05-03
US20230346794A1 (en) 2023-11-02
US12128051B2 (en) 2024-10-29
CN109789148A (zh) 2019-05-21
DK3487505T3 (da) 2023-05-30
AU2017301966B2 (en) 2022-09-22
US11759469B2 (en) 2023-09-19
SI3487505T1 (sl) 2023-10-30
AU2023203084A1 (en) 2023-06-08
EP4335517B1 (en) 2025-08-27
ES3046673T3 (en) 2025-12-02
KR102475825B1 (ko) 2022-12-08
EP4223297A2 (en) 2023-08-09
PT4335517T (pt) 2025-10-07
MX2019000946A (es) 2019-05-13
AU2017301966A1 (en) 2019-03-07
KR20240074909A (ko) 2024-05-28
KR102592614B1 (ko) 2023-10-24
CN116531386A (zh) 2023-08-04
KR20230003261A (ko) 2023-01-05
EP4223297A3 (en) 2023-11-15
WO2018019823A8 (en) 2018-04-05
AU2023203084B2 (en) 2025-03-06
US20200016165A1 (en) 2020-01-16
KR102974404B1 (ko) 2026-06-08
EP3487505A1 (en) 2019-05-29
MX385594B (es) 2025-03-18
MX2021009899A (es) 2021-09-14
KR20190031552A (ko) 2019-03-26
PT3487505T (pt) 2023-06-07
SG11201900228YA (en) 2019-02-27
US20250262219A1 (en) 2025-08-21
MY210565A (en) 2025-09-30
HRP20251365T1 (hr) 2025-12-19
HRP20230628T1 (hr) 2023-09-29
CA3031578C (en) 2025-07-08
US20220008431A1 (en) 2022-01-13
JP2019527216A (ja) 2019-09-26
DK4335517T3 (da) 2025-09-29
PL3487505T3 (pl) 2023-10-09
SI4335517T1 (sl) 2025-11-28
JP7073330B2 (ja) 2022-05-23
EP4335517A3 (en) 2024-08-07
US11065256B2 (en) 2021-07-20
EP4335517A2 (en) 2024-03-13
FI4335517T3 (fi) 2025-10-21
US20230165877A1 (en) 2023-06-01
AU2022291420A1 (en) 2023-02-02
AU2022291420B2 (en) 2024-05-09
FI3487505T3 (fi) 2023-06-05
EP4335517B8 (en) 2025-10-22
US12310973B2 (en) 2025-05-27
ES2946165T3 (es) 2023-07-13
KR20230058533A (ko) 2023-05-03
CA3031578A1 (en) 2018-02-01
MY201804A (en) 2024-03-19
WO2018019823A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
NL301322I2 (nl) Repotrectinib en/of farmaceutisch aanvaardbare zouten daarvan
IL258931A (en) Therapeutic compounds and methods
EP3709912A4 (en) DRUG DELIVERY SYSTEMS AND METHODS
DK4335517T3 (da) Indgivelse og dosering af diaminofenothiaziner
IL256652A (en) Therapeutic compositions, combinations, and methods of use
EP3558424A4 (en) DRUG DELIVERY SYSTEMS AND METHODS
IL260383B (en) Low dose therapeutic treatment
EP3463228A4 (en) INTRAOCULAR DELIVERY
PL3362084T3 (pl) Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania
DK3493862T3 (da) Lægemiddelindgivelsesanordning
HUE047477T2 (hu) Palbociclib szilárd dózisformái
EP3352757C0 (en) ADMINISTRATION OF DEUTERIUM-MODIFIED CFTR POTENTIATION AGENTS
EP3302442C0 (en) DOSAGE FORMS AND THEIR USE
DK3244948T3 (da) Bestemmelse af medikamentdosis
IL252172A0 (en) Expandable drug delivery devices and method of use
DK3278803T3 (da) Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor
LT3426285T (lt) Pegilintos urikazės kompozicijos ir dozės
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
DK3519018T3 (da) Medikamentadministrationsanordning
DK3496783T3 (da) Medikamentadministrationsanordning
DK3400045T3 (da) Medikamentadministrationsanordning
DK3380139T3 (da) Medikamentadministrationsanordning
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
DK3558438T3 (da) Lægemiddelindgivelsesanordning